银杏内酯注射液联合多巴丝肼治疗帕金森病的临床疗效

Clinical Efficacy of Ginkgolide Injection Combined with Levodopa and Benserazide in the Treatment of Parkinson's Disease

目的 分析银杏内酯联合多巴丝肼治疗帕金森病的疗效。方法 选取2021年6月—2022年6月徐州医科大学附属医院神经内科收治的100例帕金森病患者为研究对象,根据不同的治疗方法分成对照组和研究组,各50例。对照组口服多巴丝肼片,研究组在对照组基础上联用银杏内酯注射液。比较两组治疗前后统一帕金森病评定量表第Ⅲ部分(Unified Parkinson's Disease Rating Scale-Ⅲ,UPDRS-Ⅲ)评分、帕金森病生活质量问卷(Parkinson's Disease Questionnaire,PDQ-39)评分、血清同型半胱氨酸(homocysteine,Hcy)和肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)水平、不良反应发生情况。结果 治疗后研究组UPDRS-Ⅲ评分为(27.70±8.58)分,低于对照组的(32.68±10.30)分,研究组PDQ-39评分为(31.10±4.09)分,低于对照组的(36.20±6.34)分,差异有统计学意义(t=2.627、4.780,P=0.010、0.006)。治疗后两组患者Hcy、TNF-α水平下降,且研究组低于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 相比单用多巴丝肼,巴丝肼联合使用银杏内酯可以提高帕金森病患者的生活质量,降低脑血管病风险及炎症因子水平,且不良反应发生率低,有效性和安全性皆有保障。

Objective To analyze the therapeutic efficacy of ginkgolide combined with levodopa and benserazide in the treatment of Parkinson's disease.Methods A total of 100 patients with Parkinson's disease admitted to the Department of Neurology of Affiliated Hospital of Xuzhou Medical University from June 2021 to June 2022 were selected as the study objects,and they were divided into control group and study group of 50cases each according to different treatment methods.The control group was orally administered levodopa and benserazide tablets,and the study group was coadministered with ginkgolide injection on the basis of the control group.Unified Parkinson's Disease Rating Scale-Ⅲ(UPDRS-Ⅲ) scores,Parkinson's Disease Questionnaire(PDQ-39) scores,serum homocysteine(Hcy) and tumor necrosis factor-α(TNF-α) levels,and the incidence of adverse reactions were compared before and after the treatment in the two groups.Results After treatment,the UPDRS-Ⅲ score of the study group was(27.70±8.58) points,which was lower than that of the control group(32.68±10.30) points,and the PDQ-39 score of the study group was(31.10±4.09) points,which was lower than that of the control group(36.20±6.34) points,and the differences were statistically significant(t=2.627,4.780,P=0.010,0.006).The levels of Hcy and TNF-α decreased in the two groups after treatment and were lower in the study group than in the control group,and the differences were statistically significant(both P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with levodopa and benserazide alone,levodopa and benserazide combined with ginkgolides can improve the quality of life of patients with Parkinson 's disease,reduce the risk of cerebrovascular disease and inflammatory response,and the incidence of adverse reactions is small,and the efficacy and safety are guaranteed.